Business Context and Reporting Period
Pasithea Therapeutics Corp. filed this Form 8-K on December 28, 2023, under Items 3.03, 5.03, and 9.01. The filing reports a material modification to stockholder rights resulting from a reverse stock split. It does not provide operating or period-end financial results.
Key Financial and Capitalization Information
- No revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics are reported in this filing.
- The company’s common stock and warrants trade on The Nasdaq Capital Market under the symbols KTTA and KTTAW, respectively.
- The authorized number of common shares will decrease from 495,000,000 to 100,000,000.
Material Changes
- Effective at 12:01 a.m. Eastern Time on January 2, 2024, the company will implement a one-for-twenty reverse stock split of its issued and outstanding common stock.
- Every 20 shares will be converted into one share. The company expects the common stock to begin trading on a reverse-split-adjusted basis at market open on January 2, 2024.
- The common stock CUSIP will change to 70261F202.
- The reverse split will not change the $0.0001 par value of the common stock or, generally, a stockholder’s percentage ownership interest.
- Outstanding options, convertible debt, warrants, and other securities exercisable for or convertible into common stock will be adjusted as required by their terms.
- No fractional shares will be issued. Eligible holders will receive cash in lieu of fractional shares based on the average Nasdaq closing price for the five trading days preceding the effective date, adjusted for the reverse split.
Guidance, Outlook, Risks, and Unusual Items
- Stockholders approved authorizing the Board to implement a reverse split ratio ranging from 1-for-2 to 1-for-20 at the December 19, 2023 annual meeting.
- The Board selected and approved the 1-for-20 ratio on December 21, 2023, and authorized the Certificate of Amendment filing.
- The filing provides no financial guidance or operational outlook.
- The reverse split may affect the per-share trading price, share count, exercise or conversion terms of outstanding securities, and the treatment of fractional shares. The filing does not quantify these effects.
Investor Verification Items
- Verify the January 2, 2024 effective date and the commencement of reverse-split-adjusted trading.
- Confirm post-split common-share and authorized-share counts and the revised CUSIP.
- Review adjustments to outstanding warrants, options, and convertible securities.
- Review Exhibit 3.1, the Certificate of Amendment, for the complete legal terms.
- Seek separate filings for the company’s financial condition, liquidity, operating results, and financing needs, as none are provided here.